1248 results about "Gut flora" patented technology

The invention provides application of polygonatum cyrtonema polysaccharide in preparation of medicines for treating ulcerative colitis or reducing blood glucose. A main chain of a sugar chain structure of the homogeneous polysaccharide PCP2 in polygonatum cyrtonema is mainly composed of-> 1)-beta-D-Fur-(2->,-> 1, 6)-beta-D-Fur-(2-> and-> 6)-alpha-D-Glcp-(1-> and beta-D-Fur-(2->), a side chain is mainly composed of beta-D-Fur-(2-> and-> 2)-beta-D-Fur-(6-> at a C-6 position of-> 1, 6)-beta-D-Fur-(2->), Fur represents furanose, Glcp represents glucopyranose, Glcp represents glucopyranose, and Glcp represents glucopyranose. The novel polysaccharide compound can relieve intestinal injury of mice, increase expression of tight nectin and mucoprotein, relieve oxidative stress reaction, promote production of short-chain fatty acid and improve composition of intestinal flora, and can be applied to the field of medicine as a medicine for treating ulcerative colitis. Meanwhile, the homogeneous polysaccharide PCP2 in polygonatum cyrtonema can significantly inhibit the activity of alpha-amylase and alpha-glucosidase, can also promote the ability of insulin resistance 3T3-L1 fat cells to uptake and consume glucose, shows a significant hypoglycemic effect, and has a good development prospect in the aspect of preparation of hypoglycemic drugs.

The invention belongs to the technical field of medical data processing and artificial intelligence, and particularly relates to a cardiovascular disease risk prediction system based on multi-modal fusion, which comprises a multi-modal data acquisition and preprocessing module, a cross-modal association graph construction module, a dynamic fusion and prediction module based on a graph neural network and an interpretability analysis module. By constructing a heterogeneous graph fusing prior knowledge and data driving and utilizing a graph attention network to perform multi-level dynamic feature fusion, deep integration and interaction of multi-modal data such as genomes, iconography, clinical and intestinal flora metabolism are realized, so that the accuracy and interpretability of cardiovascular disease risk prediction are improved.

The invention belongs to the field of new application of medicines, and particularly relates to gastrodia elata polysaccharide and application thereof. The gastrodia elata polysaccharide component GEP-2 is separated from crude gastrodia elata polysaccharide, structural characterization detection is conducted on the GEP-2, the result shows that the gastrodia elata polysaccharide GEP-2 is prepared from, by mass, 89.08% of glucose, 2.40% of galactose, 7.12% of galacturonic acid, 0.86% of arabinose and 0.54% of rhamnose, and the animal experiment result shows that the GEP-2 relieves the symptoms of mouse colitis, relieves weight loss and shortens the colon length; the traditional Chinese medicine composition has the advantages of reducing serum TNF-alpha, IL-1beta and IL-6 proinflammatory cytokine levels, improving the intestinal barrier function, reducing inflammatory cell infiltration, regulating the intestinal flora composition structure of mice and relieving ulcerative colitis.

The invention relates to a method for identifying a disease microorganism-metabolite combined marker based on a host-flora co-metabolism model. The method comprises the following steps: processing microbiome data; setting diet constraint conditions; determining classification composition of intestinal microorganisms of each individual, mapping abundance of each microorganism to a human microorganism genome scale metabolism model, and constructing an individualized flora metabolism network model; carrying out metabolic flow simulation on the constructed flora metabolism network model; integrating the constructed flora metabolism network model with the host metabolism network model, and predicting the metabolic flow and metabolite change of the whole system; and establishing a disease classifier based on a random forest machine learning algorithm to identify the microorganism-metabolite combined marker. According to the method, the complex metabolic process between the human body and the intestinal flora is restored in a metabolic network modeling and metabolic flow simulation mode, the method has the non-invasive characteristic, the time and economic cost is remarkably reduced, and meanwhile, the method has a great advantage in accuracy.

The invention discloses bifidobacterium animalis subsp. Lactis, a preparation and application of the bifidobacterium animalis subsp. Lactis in regulation of depression and intestinal flora. Belongs to the technical field of probiotic preparation. According to the application, seven strains of bacteria are separated from excrement of infants, the seven strains of bacteria comprise bifidobacterium breve, bifidobacterium animalis and bifidobacterium longum through identification, the anti-depression capacity of the seven strains of bacteria is evaluated through in-vitro experiments, a potential antidepressant bifidobacterium animalis subsp. Lactis BD1 is screened out, and further experiments prove that the antidepressant bifidobacterium animalis subsp. Lactis BD1 has the advantages that the antidepressant bifidobacterium animalis subsp. Lactis BD1 can be used for preparing the antidepressant bifidobacterium animalis subsp. Lactis BD1; the strain has the effects of improving depressive mood, intestinal bacteria unbalance and insufficient serotonin secretion in the brain caused by chronic bound stress (CRS), and compared with bifidobacterium animalis subsp. Lactis in the prior art, the strain achieves the anti-depression effect from multiple aspects, also has the effect of adjusting intestinal flora imbalance, and has the advantages of being safe and reliable. And a new treatment strategy is provided for depression and intestinal flora imbalance.

The invention discloses a method and system for predicting juvenile depression based on intestinal flora, and relates to the technical field of bioinformatics and artificial intelligence, and the method comprises the steps: firstly, obtaining an original sequence of a microbiome, carrying out the preprocessing of the original sequence of the microbiome, and obtaining a feature matrix; and screening core flora characteristics with stable trans-folding by adopting characteristic importance evaluation and interpretability analysis based on a gradient boosting decision tree. A mixed weighted graph is constructed based on Spearman correlation and a proximity relationship, and an absolute value of a correlation coefficient is taken as an edge weight and an edge density is adjusted through a threshold adaptive strategy. And finally, through an improved graph attention neural network, based on edge weight attention, layer normalization and random inactivation, enhancing robustness, and adopting adaptive optimization to complete parameter learning. And determining a dynamic classification threshold according to the AUC of the target patient, and outputting a sample discrimination result and confidence. According to the method, the accuracy, stability and biological interpretability of juvenile depression recognition are remarkably improved.

The invention relates to the technical field of microorganisms, and particularly discloses a fermentation method of bifidobacterium longum BBMN68 as well as a fermented product, a postbiotic and application of the fermented product. According to the method for fermenting the bifidobacterium longum BBMN68, a fermentation substrate comprises alkaline protease hydrolyzed milk and a pomelo peel extract; the hydrolysis rate of the alkaline protease hydrolyzed milk is 9-11%, and the water-soluble dietary fiber content of the shaddock peel extract is 75-80%; the mass ratio of the alkaline protease hydrolyzed milk to the shaddock peel extract is (10-15): (1-3). The content of active ingredients in the fermented product prepared by the method is high, and after the fermented product is prepared into the postbiotics to be taken, the immune function of an organism can be recovered, immune organ damage is reduced, inflammation is relieved, and intestinal flora is regulated and controlled.

The invention discloses an intestinal flora marker related to juvenile depression, a product and application of the intestinal flora marker. The intestinal flora marker is prepared from any one or more of prokaryotic streptococcus parahaemolyticus, streptococcus salivarius, Alistipep and Lacnospiraceae, and the intestinal flora marker is prepared from any one or more of prokaryotic streptococcus parahaemolyticus, streptococcus salivarius, Alistipep and Lacnospiraceae, and the intestinal flora marker is prepared from any one or more of the prokaryotic streptococcus parahaemolyticus, the streptococcus salivarius, the Alistipep and the Lacnospiraceae, the prokaryotic streptococcus parahaemolyticus, the Streptococcus salivarius, the Alistipep and the Lacnospiraceae. The invention provides a kit which comprises a detection reagent for detecting the relative abundance of the intestinal flora marker. The invention provides a product for diagnosing juvenile depression and a computer program product related to the juvenile depression. The product provided by the invention has good feasibility and accuracy, can effectively evaluate the risk of depression of teenagers, and provides a new tool for clinical diagnosis.

The invention discloses lactobacillus reuteri LR69 capable of enhancing a gastric mucosal barrier and application, a product and a method thereof, and belongs to the technical field of microorganisms. The invention provides a lactobacillus reuteri LR69, and the preservation number of the lactobacillus reuteri LR69 is CGMCC (China General Microbiological Culture Collection Center) No.33731. The lactobacillus reuteri LR69 is a lactobacillus reuteri LR69. The invention also provides application of the strain in preparation of food with an auxiliary protection function on gastric mucosa, and / or food with an intestinal flora regulating function, and / or a product for relieving gastritis, and / or food with an immunity enhancing function, and / or a bacteriostatic agent. The invention further discloses a food with an auxiliary protection function on gastric mucosa, a food with an intestinal flora regulating function, a product for relieving gastritis, a food with an immunity enhancing function, a bacteriostatic agent and an in-vitro bacteriostasis method based on the strain. The lactobacillus reuteri LR69 disclosed by the invention can effectively assist in protecting gastric mucosa, regulating intestinal flora, relieving gastritis, enhancing immunity and realizing broad-spectrum bacteriostasis.

The invention discloses a medicinal and edible homologous compound based on probiotic fermentation synergy and application of the medicinal and edible homologous compound in blood sugar regulation and control, and belongs to the technical field of microorganisms and fermentation engineering. The preparation method comprises the following steps: respectively carrying out two-stage fermentation on aloe, mulberry leaves and liquorice by utilizing saccharomyces cerevisiae BLCC4-0032 and plant lactobacillus DFR-1, so as to obtain a fermentation mixture; the preparation method comprises the following steps: fermenting a fermentation mixture, adding balsam pear peptide into the fermentation mixture to obtain a medicinal and edible compound, forming a metabolic closed loop, and cooperatively regulating a'blood sugar-liver-intestinal flora axis', thereby providing a new solution for diabetes intervention, and opening up a new path for preventing non-alcoholic fatty liver and intestinal inflammation caused by glucose and lipid metabolism disorder.

The invention discloses bifidobacterium longum subsp.infantis capable of promoting bone growth and a metagen thereof, and belongs to the technical field of biology. The bifidobacterium longum subsp. Infantis CCFM1445 provided by the invention can promote the increase of bone volume fraction, femoral bone trabecula thickness and far-end growth plate thickness of mammals in a growth period, reduce the levels of serum bone resorption markers I-type collagen amino-terminal peptide and tartrate-resistant acid phosphatase, improve the levels of serum bone alkaline phosphatase and parathyroid hormone, and improve the clinical application value of the bifidobacterium longum subsp. Infantis CCFM1445. And the relative abundance of the other bacteria in the intestinal flora and the levels of creatine and indole-3-lactic acid are increased. The thermally inactivated bifidobacterium longum subsp. Infantis CCFM1445 can promote the increase of the volume fraction of femoral bones and the number of bone trabecula of malnourished mice and improve the N-terminal propeptide level of serum I-type procollagen. Therefore, the medicine or health care product prepared from the bifidobacterium longum subsp. Infantis CCFM1445 can be used for assisting in regulating bone metabolism and bone mass, and has a wide market prospect.

The present invention discloses a Bifidobacterium breve strain capable of clearing toxins in the body and its postbiotics, belonging to the technical field of microbial applications. The present invention isolates a Bifidobacterium breve strain ( Bifidobacterium breve ) WZA-BB07 from human feces, and its biological deposit number is: CCTCC NO: M20241530. The strain WZA-BB07 has good effects in degrading endotoxin and enterotoxin. The strain and Lactobacillus mucosae are mixed and fermented to prepare postbiotics. Bifidobacterium breve mainly improves the balance of intestinal flora and inhibits the growth of harmful bacteria. Lactobacillus mucosae helps repair the intestinal barrier through its metabolites during fermentation, enhancing the metabolism and clearance of toxins; extracts of Dendrobium officinale, Lonicera japonica, and Pueraria lobata are added to the fermentation medium, which not only provides rich nutrition for fermentation but also exerts the antioxidant, anti-inflammatory, and intestinal repair-promoting effects of ingredients with both medicinal and edible properties, further enhancing the detoxification ability and overall health effects of the postbiotic product.

A Bifidobacterium longum subsp. infantis YLGB-1496 postbiotic product, a bacteriocin, a preparation method, and a use, specifically relating to the technical field of probiotic postbiotics. The provided probiotic postbiotic product has the following biological functions: enhancing the intestinal barrier function, preventing and / or treating inflammatory bowel diseases, regulating gut flora, relieving intestinal flatulence and resisting oxidation, and has application prospects in preparing health-care foods or drugs for regulating gut flora and resisting oxidation.

The invention belongs to the technical field of food functional ingredient nutriology research, and discloses application of narirutin in improving the intestinal flora homeostasis of food allergy organisms. The narirutin can adjust the relative abundance value of certain intestinal flora by adjusting the diversity of the intestinal flora of a food allergy body, improve the relative abundance of beneficial bacteria and harmful bacteria, and can influence the metabolism of short-chain fatty acid of the intestinal flora of the food allergy body, so that the food allergy body is improved. Further, the application of the narirutin in improving the intestinal flora homeostasis of food allergy organisms is realized. The application of narirutin in the research fields of nutriology, biology and pharmacology is expanded.

The invention relates to application of bifidobacterium breve BBr60 in preparation of a probiotic preparation for improving atopic dermatitis. The bifidobacterium breve BBr60 is a bifidobacterium breve BBr60 strain of which the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.12915, and the bifidobacterium breve BBr60 strain of which the preservation number is CGMCC No.12915. The invention develops a new application of the bifidobacterium breve BBr60, provides a research basis for wide application of the bifidobacterium breve BBr60, also develops a brand new strategy for improving atopic dermatitis, discovers that the bifidobacterium breve BBr60 has a very remarkable effect on improving atopic dermatitis, and has a very good application prospect. Specifically, the skin lesion phenomenon and the mast cell inflammation infiltration phenomenon in the skin of an atopic dermatitis model mouse are remarkably improved; the IgE level in serum of an atopic dermatitis model mouse is remarkably reduced and improved, the levels of IFN-gamma and IL-10 are improved, and Th1 / Th2 immune balance is recovered; the intestinal flora uniformity of atopic dermatitis model mice is recovered, and the relative abundance and F / B ratio of bifidobacterium and lactobacillus in the intestinal flora of the mice are remarkably improved.

The invention discloses an application of pleurotus eryngii purified polysaccharide in preparation of an intestinal care medicine. The pleurotus eryngii purified polysaccharide component has high immunocompetence, high-activity and high-purity polysaccharide is obtained after ethanol precipitation and organic solvent purification, and the high biological activity of the polysaccharide is reserved; the composition has the biological activity of increasing the production of short-chain fatty acid, reducing the inflammation level, improving the intestinal flora structure, influencing the body metabolism condition and protecting the intestinal barrier. Compared with other components in the pleurotus eryngii polysaccharide extraction process, the polysaccharide component obtained by the preparation method has the highest purity and the strongest biological activity, and can be used for preparing intestinal care medicines.

The invention discloses a non-invasive intestinal flora fixed-point sampling and drug release device, and belongs to the technical field of micro-ecological diagnosis and treatment. The device comprises a shell, an internal storage bin, a medicine loading cavity and a channel switching mechanism. The shell adopts a capsule-shaped design, and an enteric coating is arranged on the surface of the shell, so that the function is started after the shell reaches a specified position of an intestinal tract. Through the internal ingenious mechanism linkage design, the device can firstly complete non-invasive fixed-point sampling of intestinal contents, and after the sampling action is completed, a drug release mechanism is automatically triggered, so that accurate drug delivery of the same part is realized. Cooperative operation of sampling and drug release in time sequence and space is achieved, and the problems of pain, disjunction of the diagnosis and treatment process, poor drug targeting and the like caused by traditional invasive operation are effectively solved. The device is flexible in structural design, has the advantages of being noninvasive, efficient, accurate in time sequence control and the like, and is suitable for integrated application of diagnosis and treatment of various digestive tract diseases such as inflammatory bowel disease management, micro-ecological regulation and the like.

The invention relates to the technical field of critical nutrition medical treatment, and discloses a critical patient enteral nutrition diarrhea risk prediction model system. A nutrition parameter acquisition module of the system is used for acquiring enteral nutrition formula parameters, including nutrient solution osmotic pressure, infusion speed and nutrient solution temperature, of a critical patient; the physiological index analysis module is used for collecting intestinal flora abundance data, serum albumin level and gastrointestinal peristalsis frequency of the critical patient; the risk feature extraction module is used for calculating an intestinal tolerance feature value according to the enteral nutrition formula parameters and the intestinal flora abundance data; and the prediction model construction module is used for constructing a diarrhea risk prediction model based on the intestinal tolerance characteristic value and the serum albumin level. According to the system, comprehensive acquisition and analysis of enteral nutrition related data of critical patients can be realized, objectivity and accuracy of diarrhea risk prediction are improved, and support is provided for clinical enteral nutrition scheme adjustment and diarrhea prevention.

The invention discloses an extraction method of coriolus versicolor polysaccharide. The method comprises the steps of crude extraction of the coriolus versicolor polysaccharide and purification of the coriolus versicolor polysaccharide. The crude extraction of coriolus versicolor polysaccharide comprises the following steps: water extraction and alcohol precipitation, H2O2 decoloration and freeze-drying; the purification of the coriolus versicolor polysaccharide comprises the following steps: carrying out anion exchange column chromatography on a coriolus versicolor polysaccharide crude product obtained by crude extraction of the coriolus versicolor polysaccharide, and carrying out ultrafiltration separation and purification to obtain the refined coriolus versicolor polysaccharide. The coriolus versicolor polysaccharide with the polysaccharide content of 80.18% and the protein content of 5.9% can be obtained through the preparation method. HPGPC analysis shows that the coriolus versicolor polysaccharide is uniform in molecular weight distribution, and the relative molecular weight Mw is about 17478 Da. The coriolus versicolor polysaccharide plays a role in treating the NAFLD by regulating intestinal flora and influencing bile acid metabolism, a theoretical basis is provided for treating the NAFLD by the coriolus versicolor polysaccharide, and a direction is broadened for NAFLD medicine development.

The invention discloses application of a stem cell exosome in treating depression-like behaviors caused by high-altitude hypoxia, and belongs to the technical field of biomedicine. The stem cell exosome is an exosome derived from human umbilical cord mesenchymal stem cells, and is used for drugs for preventing and / or treating depression-like behaviors caused by high-altitude hypoxia. The exosome can effectively improve depression-like core behavior symptoms caused by high-altitude hypoxia by regulating a brain-intestinal axis; the method starts from remodeling intestinal flora so as to influence the intracerebral metabolite spectrum, and finally plays a role in neuroprotection by regulating and controlling a 5-HT6 / cAMP-PKA key signal channel. In addition, the combination of the hUC-MSC-exo and probiotics shows synergistic interaction potential, and a potential treatment strategy which is novel in mechanism, remarkable in effect and high in safety is provided for the field.

The invention relates to the technical field of health evaluation, in particular to a group image health evaluation method and system based on intestinal flora, and the method comprises the steps: collecting intestinal flora samples of a target group through a standardized process, and obtaining microbial sequence information through a high-throughput sequencing technology; microflora diversity characteristics and core flora characteristics are extracted through strain identification and relative abundance analysis, individual flora characteristics are compared with a healthy population reference database, health state scores are calculated, health grades are divided, population health grade distribution is counted, and the population health grade distribution is calculated. And generating a group health evaluation report containing a visual chart and text analysis. According to the method, a complete technical system from sample collection to health strategy making is established, systematic evaluation of the group health state from the perspective of intestinal flora is achieved, and the limitation of a traditional method in group health early evaluation is overcome. The method is suitable for health monitoring of different scales of groups, and provides effective technical support for public health management and health service.

The invention discloses a lactobacillus buchneri complex microbial inoculant and application thereof, and belongs to the technical field of microorganisms. In order to solve the problem of poor direct degradation effect of lactic acid bacteria on uric acid in the prior art, the invention provides a complex microbial inoculant containing lactobacillus buchneri NEFU-1 and NEFU-2, and the complex microbial inoculant has the functions of degrading uric acid, relieving hyperuricemia, degrading inosine and / or guanosine, improving intestinal flora composition and reducing inflammatory factors; the lactobacillus plantarum has important significance on preventing, improving and treating gout and hyperuricemia diseases, has high application value and can be applied to preparation of fermented yoghurt.

The invention discloses a novel method for food allergy intestinal flora target mining, and belongs to the technical field of target mining. The new method comprises the following steps: acquiring whole genome associated GWAS data and intestinal flora related data of food allergy; performing tool variable screening and multi-effect removal on the collected data; according to the collected tool variables, analyzing the data by adopting a bidirectional Mendel randomization method to obtain a preliminary screening result of the causal flora; the preliminary screening result is analyzed, and candidate tool variables are obtained by integrating effect values of multiple analysis methods and judgment of sensitivity analysis; establishing a food allergy animal model; carrying out targeted determination on the screened related flora having a causal relationship with food allergy by adopting a microbiological analysis method; and the active small molecules act on the target flora to determine the reliability of the active small molecules as the food allergy target. According to the method, the intestinal flora and the target flora of food allergy can be determined.

The invention provides application of pediococcus pentosaceus in preparation of a product for improving pork quality and intestinal flora, and relates to the technical field of animal feeding. The pediococcus pentosaceus disclosed by the invention is pediococcus pentosaceus LL2018368, is separated from the digestive tract of a Diqing Tibetan pig and is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC No.18709. The pediococcus pentosaceus disclosed by the invention has the advantages that the pediococcus pentosaceus can be used for preparing the pediococcus pentosaceus; the pediococcus pentosaceus LL2018368 is added into drinking water of the Du-Si pigs, the influence of the pediococcus pentosaceus LL2018368 on archaea, meat quality, tissue fat-soluble vitamins and excrement metabolite composition in the excrement of the Du-Si pigs is studied, and the result shows that the pediococcus pentosaceus LL2018368 enables the species of the archaea in the excrement to tend to be consistent, so that the content of the archaea in the excrement of the Du-Si pigs in the excrement of the Du-Si pigs in the excrement of the Du-Si pigs is increased. The contents of vitamin A and all-trans-retinol in kidney tissues are increased, and the probiotic functions of amino acid and fat metabolism related bacteria and enzymes are improved.

The invention discloses a fat-reducing and weight-reducing medicinal and edible food and a preparation method thereof, the composition comprises a lotus leaf extract, a Pu'er tea fermentation product, a hovenia dulcis thunb extract, konjac glucomannan, a pepper extract, fermented mulberry leaf powder, a prebiotic compound and oyster peptide, and the invention relates to the technical field of functional food. According to the fat-reducing and weight-reducing medicinal and edible food and the preparation method thereof, efficient fat reduction is realized through a four-dimensional synergistic effect (regulating lipid metabolism, inhibiting fat absorption, promoting energy consumption and improving intestinal flora).

The invention relates to the technical field of food processing, and discloses Lithocarpus litseifolius low-GI biscuits with an intestinal flora regulation function and a preparation method thereof.The preparation method comprises the following specific steps that Lithocarpus litseifolius tender leaves are spread, aired, roasted, rolled and dried and then made into Lithocarpus litseifolius ultra-fine powder with the specific particle size (300-900 meshes) through an ultra-fine crushing technology, and the Lithocarpus litseifolius ultra-fine powder with the specific particle size (300-900 meshes) is prepared into the Lithocarpus litseifolius low-GI biscuits. And then compounding the Lithocarpus litseifolius with wheat flour to prepare the Lithocarpus litseifolius biscuit. The Lithocarpus litseifolius low-GI biscuit prepared by the method is low in GI value, belongs to medium-GI food, overcomes the defects of high glycemic content and low dietary fiber content of traditional biscuits, is unique in taste and balanced in nutrition, can increase the content of short-chain fatty acid SCFAs in intestinal tracts, has the effects of regulating intestinal flora, maintaining blood sugar balance and reducing fat, and can be used for preparing the low-GI biscuit for the Lithocarpus litseifolius low-GI biscuit. The method has a wide prospect and a high market value.

The present invention discloses a microecological animal model for obstructive sleep apnea syndrome, which includes steps such as constructing a fitting model for the changing trend of OSA events, selecting target animals and performing pretreatment, preparing an animal model, obtaining fecal samples, and DNA extraction and 16S rRNA high-throughput sequencing. By constructing a fitting model for the changing trend of respiratory sleep apnea events, the present invention obtains the fitting mathematical relationship between the number of apnea and time, and establishes an animal model with SD rats. According to the obtained fitting mathematical relationship, the animal model of the experimental group is given periodic oxygen supply to establish an intestinal flora model for studying obstructive sleep apnea syndrome, which can simulate the actual physiological environment during sleep of patients. According to the changing trend of the duration of patients' respiratory sleep apnea events, a microecological animal model more consistent with the actual situation is established, making the detection result of the flora structure more accurate.

The present invention belongs to the field of biomedicine technology, and specifically relates to a strain of Lactobacillus plantarum YYY01 and its application in anti-inflammatory and production of γ-aminobutyric acid. The Lactobacillus plantarum YYY01 provided by the present invention is deposited with GDMCC NO: 65147. The Lactobacillus plantarum YYY01 has good biosafety, survives well in the gastrointestinal environment and has a certain intestinal adhesion ability; Lactobacillus plantarum YYY01 can produce high γ-aminobutyric acid, has anti-inflammatory, intestinal flora regulation and immune barrier enhancement effects. It shows good application prospects in increasing the yield of γ-aminobutyric acid and preparing products containing γ-aminobutyric acid.

The invention discloses a fermented traditional Chinese medicine feed additive as well as a preparation method and application thereof, and belongs to the technical field of traditional Chinese veterinary medicines. The additive is prepared by solid state fermentation and extraction of a traditional Chinese medicine composition and a complex microbial inoculant, the traditional Chinese medicine composition comprises poria cocos, astragalus membranaceus, codonopsis pilosula, pericarpium citri reticulatae and radix puerariae, and the complex microbial inoculant comprises bacillus subtilis, lactobacillus plantarum and aspergillus niger. Through a fermentation and extraction combined process, the effective components in the traditional Chinese medicines are higher in extraction rate and easier to absorb, the animal intestinal flora balance can be remarkably regulated, the immunity is enhanced, the growth performance is promoted, and the prospect is wide.

The invention discloses application of phlebopus portentosus polysaccharide in preparation of medicines or foods for regulating intestinal flora, reducing blood fat and reducing weight, and belongs to the technical field of biological medicines. The research on the effect of the phlebopus portentosus polysaccharide on obese model mice finds that the polysaccharide can reduce the occurrence of cardiovascular diseases such as atherosclerosis and the like, and has the effect of protecting the liver from being damaged. In addition, the liver injury state of the obese mouse is obviously relieved, the content of total short-chain fatty acid (SCFAs) of the obese mouse is increased, the species diversity of intestinal flora of the mouse is adjusted to a certain extent, and the colony composition is optimized.